Skip to main content
Erschienen in: Rheumatology International 5/2020

01.05.2020 | Case Based Review

Systemic lupus erythematosus and hydroxychloroquine-related acute intermittent porphyria

verfasst von: Enrique Esteve-Valverde, Alfonso Tapiz-Reula, Domingo Ruiz, Jaume Alijotas-Reig

Erschienen in: Rheumatology International | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Porphyrias, particularly acute intermittent porphyria (AIP), are rare disorders which could be associated with systemic lupus erythematosus (SLE). Although the association with AIP has been known since 1952, only 11 cases have been published to date. It is widely known that precipitating causes such as infections, hormonal changes, sunlight exposure, stress and drugs could provoke an AIP crisis. Hydroxychloroquine (HCQ) is usually used in lupus patients, but rarely appears to trigger AIP crises even in SLE patients. The case of a 51-year-old man in whom AIP onset was probably due to hydroxychloroquine use during SLE management is presented. SLE onset was accompanied by fever, pleural, lung and joint involvement with a characteristic SLE autoantibody panel. Although prednisone was given, the joint symptoms did not subside. HCQ was then started; however, some days later the patient suffered anxiety, vomiting and severe abdominal pain refractory to pain-relief drugs and liver function had worsened. No cutaneous lesions were observed. The patient suffered similar episodes accompanied by paralytic ileus and dark-coloured urine, the sediment of which showed no abnormalities. In addition, no myoglobinuria was found. This finding raised the suspicion of AIP and urine tests revealed elevated values of delta-aminolevulinic acid and porphobilinogen. Hydroxychloroquine was preventively suspended and the patient improved notably within a few days. In the following months, the patient suffered no relapse and the prednisone dose could be lowered. Finally, a review of the literature on this topic highlighted the exceptional nature of an API/ SLE association particularly in men. Interestingly, porphyria may present first followed by SLE, or vice versa. The latency period between drug administration and disease onset varies from days to 2 years. Both chloroquine and HCQ may induce PAI in SLE patients. Clinicians should be alerted to a possible association with AIP when a patient with SLE recently put on HCQ presents acute onset of abdominal and/or neurological symptoms and dark urine. Appropriate tests and prompt HCQ cessation are mandatory.
Literatur
1.
Zurück zum Zitat Desnick RJ, Balwani M (2015) The Porphyrias. In: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J (eds) Harrison’s principles of internal medicine, 19th edn. McGraw Hill, New York, pp 2521–2533 Desnick RJ, Balwani M (2015) The Porphyrias. In: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J (eds) Harrison’s principles of internal medicine, 19th edn. McGraw Hill, New York, pp 2521–2533
2.
Zurück zum Zitat Wolfram S (1952) Uber Porphyrinkolik, Ein Beitrag zur Symptomatologie des Erythematodes Acutus. Hautarzt 3:298–300PubMed Wolfram S (1952) Uber Porphyrinkolik, Ein Beitrag zur Symptomatologie des Erythematodes Acutus. Hautarzt 3:298–300PubMed
3.
Zurück zum Zitat Allard SA, Charles PJ, Herrick AL, McColl KEL, Scott TJ (1990) Antinuclear antibodies and the diagnosis of systemic lupus erythematosus in patients with acute intermitent porphyria. Ann Rheum Dis 49:246–248PubMedPubMedCentralCrossRef Allard SA, Charles PJ, Herrick AL, McColl KEL, Scott TJ (1990) Antinuclear antibodies and the diagnosis of systemic lupus erythematosus in patients with acute intermitent porphyria. Ann Rheum Dis 49:246–248PubMedPubMedCentralCrossRef
4.
Zurück zum Zitat Filiotou A, Vaiopoulos G, Capsimali V, Stavrianeas N, Kaloterakis A (2002) Acute intermittent porphyria and systemic lupus erythematosus: report of a case and review of the literature. Lupus 11:190–192PubMedCrossRef Filiotou A, Vaiopoulos G, Capsimali V, Stavrianeas N, Kaloterakis A (2002) Acute intermittent porphyria and systemic lupus erythematosus: report of a case and review of the literature. Lupus 11:190–192PubMedCrossRef
5.
Zurück zum Zitat Ponticelli C, Moroni G (2017) Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin Drug Saf 16:411–419PubMedCrossRef Ponticelli C, Moroni G (2017) Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin Drug Saf 16:411–419PubMedCrossRef
6.
Zurück zum Zitat Rigor J, Pinto SA, Martins-Mendes D (2019) Porphyrias: a clinically based approach. Eur J Intern Med 67:24–29PubMedCrossRef Rigor J, Pinto SA, Martins-Mendes D (2019) Porphyrias: a clinically based approach. Eur J Intern Med 67:24–29PubMedCrossRef
8.
Zurück zum Zitat Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725CrossRef Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725CrossRef
9.
Zurück zum Zitat Petri M, Orbai A-M, Alarcón GS, Gordon C, Merrill JT, Fortin PR et al (2012) Derivation and validation of Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–2686PubMedPubMedCentralCrossRef Petri M, Orbai A-M, Alarcón GS, Gordon C, Merrill JT, Fortin PR et al (2012) Derivation and validation of Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–2686PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Stein PE, Badminton MN, Rees DC (2017) Update review of the acute porphyrias. Br J Haematol 176:527–538PubMedCrossRef Stein PE, Badminton MN, Rees DC (2017) Update review of the acute porphyrias. Br J Haematol 176:527–538PubMedCrossRef
13.
Zurück zum Zitat Sunkara B, Roofeh D, Silver S, LeBleu PT, Ettel M, McCune WJ (2018) The devil’s in the dosing: severe drug-induced liver injury in a hydroxychloroquine-naïve patient with subacute cutaneous lupus erythematosus and porphyria cutanea tarda. Lupus 27:1383–1386PubMedCrossRef Sunkara B, Roofeh D, Silver S, LeBleu PT, Ettel M, McCune WJ (2018) The devil’s in the dosing: severe drug-induced liver injury in a hydroxychloroquine-naïve patient with subacute cutaneous lupus erythematosus and porphyria cutanea tarda. Lupus 27:1383–1386PubMedCrossRef
14.
Zurück zum Zitat Liu HM, Deng GH, Mao Q, Wang XH (2019) Diagnosis of erythropoietic protoporphyria with severe liver injury: a case report. World J Gastroenterol 25:880–887PubMedPubMedCentralCrossRef Liu HM, Deng GH, Mao Q, Wang XH (2019) Diagnosis of erythropoietic protoporphyria with severe liver injury: a case report. World J Gastroenterol 25:880–887PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Hammersland MH, Aarsand AK, Sandberg S, Andersen J (2019) Self-efficacy and self-management strategies in acute intermittent porphyria. BMC Health Serv Res 19:444PubMedPubMedCentralCrossRef Hammersland MH, Aarsand AK, Sandberg S, Andersen J (2019) Self-efficacy and self-management strategies in acute intermittent porphyria. BMC Health Serv Res 19:444PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat De Siervi A, Varela LS, Parera VE, Batlle A, Rossetti MV (2001) Diagnosis of latent acute intermittent porphyria by genetic analysis. Ann Clin Biochem 38:149–152PubMedCrossRef De Siervi A, Varela LS, Parera VE, Batlle A, Rossetti MV (2001) Diagnosis of latent acute intermittent porphyria by genetic analysis. Ann Clin Biochem 38:149–152PubMedCrossRef
17.
Zurück zum Zitat Raigal MY, Navarro JL, Martín JMR, Patino EM, Pérez EP, Prat MM (2008) Acute intermittent porphyria and chronic transaminases elevation. Gastroenterol y Hepatol 31:225–228CrossRef Raigal MY, Navarro JL, Martín JMR, Patino EM, Pérez EP, Prat MM (2008) Acute intermittent porphyria and chronic transaminases elevation. Gastroenterol y Hepatol 31:225–228CrossRef
19.
20.
Zurück zum Zitat Passaron N, Loveras JH, Vasquez E (1962) Lupus erythematoso crónico exacerbado y porfiria aguda. Arch Argent Dermatol 12:299–303PubMed Passaron N, Loveras JH, Vasquez E (1962) Lupus erythematoso crónico exacerbado y porfiria aguda. Arch Argent Dermatol 12:299–303PubMed
21.
Zurück zum Zitat Harris MY, Mills GL, Levin WC (1966) Coexistent systemic lupus erythematosus and porphyria. Arch Intern Med 117:425–428CrossRef Harris MY, Mills GL, Levin WC (1966) Coexistent systemic lupus erythematosus and porphyria. Arch Intern Med 117:425–428CrossRef
22.
Zurück zum Zitat Quilichini R, Guerder A (1973) Systemic lupus erythematosus and acute intermittent porphyria. Nouv Press Med 2:1074 Quilichini R, Guerder A (1973) Systemic lupus erythematosus and acute intermittent porphyria. Nouv Press Med 2:1074
23.
Zurück zum Zitat Vittori F, Desaegher JL (1977) Lupus erythemateux disemine et porphyrie aigue intermittente. Association ou coincidence? Sem Hop Paris 53:1542–1548PubMed Vittori F, Desaegher JL (1977) Lupus erythemateux disemine et porphyrie aigue intermittente. Association ou coincidence? Sem Hop Paris 53:1542–1548PubMed
24.
Zurück zum Zitat Rosemarin JI, Nigro EJ, Levere NR, Mascarenhas BR (1982) Systemic lupus erythematosus and acute intermittent porphyria: coincidence or association? Arthritis Rheum 25:1134–1137PubMedCrossRef Rosemarin JI, Nigro EJ, Levere NR, Mascarenhas BR (1982) Systemic lupus erythematosus and acute intermittent porphyria: coincidence or association? Arthritis Rheum 25:1134–1137PubMedCrossRef
25.
Zurück zum Zitat Allard SA, Scott JT (1989) Systemic lupus erythematosus and acute intermittent porphyria. Br J Rheumatol 28:254–256PubMedCrossRef Allard SA, Scott JT (1989) Systemic lupus erythematosus and acute intermittent porphyria. Br J Rheumatol 28:254–256PubMedCrossRef
26.
Zurück zum Zitat Andersson C, Lithner F (1994) Hypertension and renal disease in patients with acute intermittent porphyria. J Intern Med 236:169–175PubMedCrossRef Andersson C, Lithner F (1994) Hypertension and renal disease in patients with acute intermittent porphyria. J Intern Med 236:169–175PubMedCrossRef
27.
Zurück zum Zitat Bharati A, Kleyn E, Wong GA, Leonard N, King CM (2007) A spectrum of lupus erythematosus from verrucous to systemic, coexisting with two types of porphyria. J Eur Acad Dermatol Venereol 21:1009–1010PubMedCrossRef Bharati A, Kleyn E, Wong GA, Leonard N, King CM (2007) A spectrum of lupus erythematosus from verrucous to systemic, coexisting with two types of porphyria. J Eur Acad Dermatol Venereol 21:1009–1010PubMedCrossRef
28.
Zurück zum Zitat Patil AD, Karnik ND, Nadkar MY, Gupta VA, Muralidhara K, Passidhi S (2015) Guillain Barré syndrome, systemic lupus erythematosus and acute intermittent porphyria—a deadly trio. J Assoc Physicians India 63:60–63PubMed Patil AD, Karnik ND, Nadkar MY, Gupta VA, Muralidhara K, Passidhi S (2015) Guillain Barré syndrome, systemic lupus erythematosus and acute intermittent porphyria—a deadly trio. J Assoc Physicians India 63:60–63PubMed
29.
Zurück zum Zitat Korkmaz C (2006) Delayed diagnosis of porphyria based on manifestations of systemic lupus erythematosus and ankylosing spondylitis. J Nephrol 19:535–539PubMed Korkmaz C (2006) Delayed diagnosis of porphyria based on manifestations of systemic lupus erythematosus and ankylosing spondylitis. J Nephrol 19:535–539PubMed
30.
Zurück zum Zitat Bonkovsky HL, Maddukuri VC, Yazici C, Anderson KE, Bissell DM, Bloomer JR et al (2014) Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium. Am J Med 127:1233–1241PubMedPubMedCentralCrossRef Bonkovsky HL, Maddukuri VC, Yazici C, Anderson KE, Bissell DM, Bloomer JR et al (2014) Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium. Am J Med 127:1233–1241PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Lisnevskaia L, Murphy G, Isenberg D (2014) Systemic lupus erythematosus. Lancet 384:1878–1888PubMedCrossRef Lisnevskaia L, Murphy G, Isenberg D (2014) Systemic lupus erythematosus. Lancet 384:1878–1888PubMedCrossRef
33.
Zurück zum Zitat Roveri G, Nascimbeni F, Rocchi E, Ventura P (2014) Drugs and acute porphyrias: reasons for a hazardous relationship. Postgrad Med 126:108–120PubMedCrossRef Roveri G, Nascimbeni F, Rocchi E, Ventura P (2014) Drugs and acute porphyrias: reasons for a hazardous relationship. Postgrad Med 126:108–120PubMedCrossRef
34.
Zurück zum Zitat Chang C, Gershwin ME (2011) Drug-induced lupus erythematosus: incidence, management and prevention. Drug Saf 34:357–374PubMedCrossRef Chang C, Gershwin ME (2011) Drug-induced lupus erythematosus: incidence, management and prevention. Drug Saf 34:357–374PubMedCrossRef
35.
Zurück zum Zitat -Chalumeau N, Dunogué B, Morel N, Le Guern V, Guettrot-Imbert G (2014) Hydroxychloroquine: a multifaceted treatment in lupus. Presse Med 43(2):e167–e180PubMedCrossRef -Chalumeau N, Dunogué B, Morel N, Le Guern V, Guettrot-Imbert G (2014) Hydroxychloroquine: a multifaceted treatment in lupus. Presse Med 43(2):e167–e180PubMedCrossRef
36.
Zurück zum Zitat Fritzler MJ, Rubin RL (1994) Drug-induced lupus. In: Wallace DJ, Hahn BH (eds) Dubois’ lupus erythematosus, 4th edn. Lea & Febiger, Philadelphia, pp 442–453 Fritzler MJ, Rubin RL (1994) Drug-induced lupus. In: Wallace DJ, Hahn BH (eds) Dubois’ lupus erythematosus, 4th edn. Lea & Febiger, Philadelphia, pp 442–453
37.
Zurück zum Zitat Zvi I, Kivity S, Langevitz P, Shoenfeld Y (2012) Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 42:145–153PubMedCrossRef Zvi I, Kivity S, Langevitz P, Shoenfeld Y (2012) Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 42:145–153PubMedCrossRef
38.
Zurück zum Zitat Spinelli FR, Moscarelli E, Ceccarelli F, Miranda F, Perricone C, Truglia S et al (2018) Treating lupus patients with antimalarials: analysis of safety profile in a single-center cohort. Lupus 27:1616–1623PubMedCrossRef Spinelli FR, Moscarelli E, Ceccarelli F, Miranda F, Perricone C, Truglia S et al (2018) Treating lupus patients with antimalarials: analysis of safety profile in a single-center cohort. Lupus 27:1616–1623PubMedCrossRef
39.
Zurück zum Zitat Alijotas-Reig J (2013) Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management. Lupus 22:6–17PubMedCrossRef Alijotas-Reig J (2013) Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management. Lupus 22:6–17PubMedCrossRef
40.
Zurück zum Zitat Wallace DJ (1996) The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review. Lupus 5(1):S59–64PubMedCrossRef Wallace DJ (1996) The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review. Lupus 5(1):S59–64PubMedCrossRef
41.
Zurück zum Zitat Kalia S, Dutz JP (2007) New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther 20:160–174PubMedCrossRef Kalia S, Dutz JP (2007) New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther 20:160–174PubMedCrossRef
42.
Zurück zum Zitat Arora S, Young S, Kodali S, Singal AK (2016) Hepatic porphyria: a narrative review. Indian J Gastroenterol 35:405–418PubMedCrossRef Arora S, Young S, Kodali S, Singal AK (2016) Hepatic porphyria: a narrative review. Indian J Gastroenterol 35:405–418PubMedCrossRef
43.
Zurück zum Zitat Petersen CS, Thomsen K (1992) High-dose hydroxychloroquine treatment of porphyria cutanea tarda. J Am Acad Dermatol 26:614–619PubMedCrossRef Petersen CS, Thomsen K (1992) High-dose hydroxychloroquine treatment of porphyria cutanea tarda. J Am Acad Dermatol 26:614–619PubMedCrossRef
Metadaten
Titel
Systemic lupus erythematosus and hydroxychloroquine-related acute intermittent porphyria
verfasst von
Enrique Esteve-Valverde
Alfonso Tapiz-Reula
Domingo Ruiz
Jaume Alijotas-Reig
Publikationsdatum
01.05.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 5/2020
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-019-04500-8

Weitere Artikel der Ausgabe 5/2020

Rheumatology International 5/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.